7 results
Profiles of Antidiabetic Medications - AACE 2018 

#Antidiabetic #Medications #Profiles #SideEffects #Table #DecisionAid #Orals #DM2 #Diabetes
of Antidiabetic Medications ... #Profiles #SideEffects ... DecisionAid #Orals #DM2 ... #Diabetes #Endocrinology ... #Pharmacology #
Diabetes Medication Choice
-Diabetes Medication Choice decision aid cards provide information on medications commonly used to treat
Diabetes Medication ... interest to the patient ... Diabetes #Type2 #DM2 ... #Selection #SideEffects ... Reduction #Costs #Pharmacology
DPP4 Inhibitors - Normal and Renal Dosing

Increase Incretins (GLP-I & GIP) -> Stimulates Insulin, Inhibits Glucagon
If you see a patient ... very tolerable medication ... Renal #Dosing #Pharmacology ... Management #Diabetes #DM2 ... #Endocrinology
Diabetes Mellitus Type 2 Inpatient Medication Guide

Classes: Biguanide, Sulfonylurea, TZD, DPP-4 inhibitor, GLP-1 receptor agonist, SGLT2i,
Sulfonylurea, TZD, DPP ... Diabetes #Mellitus #DM2 ... #Inpatient #Medications ... #pharmacology # ... comparison #table #endocrinology
GLP-1 Agonists

Adlyxin (Lixisenatide) Daily
Bydureon (Exenatide ER) Weekly 
Ozempic (Semaglutide) Weekly 
Trulicity (Dulaglutide) Weekly 
Victoza (Liraglutide) Daily
commonly used medications ... very similar to DPP4s ... GLP1 #Agonists #Pharmacology ... Dosing #Diabetes #DM2 ... #Endocrinology
SGLT2 Inhibitors 
SGLT2 inhibitors are the newest class of anti-diabetic medications, with the first one (Canagliflozin)
anti-diabetic medications ... which causes the patient ... SGLT2 #Inhibitors #Pharmacology ... #Medications #DM2 ... #Diabetes #Endocrinology
Rybelsus (oral semaglutide) - First Oral GLP-1 Agonist
Dosing:
3 mg daily x 30 days, then 7 mg
semaglutide, the same medication ... been shown non-inferior ... empagliflozin and DPP4 ... semaglutide #Diabetes #Pharmacology ... #Endocrinology